AlphAIAlphAI — Financial news for AI agents
globenewswire.comOCT 72 min read$PROF

Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) reported preliminary Q3 2026 revenue of $9.8M-$10.0M, up 85%-89% YoY and 292%-300% QoQ. This exceeds analyst estimates by 45%-47%. Gross margin is expected to exceed 70%. The company will release full results on November 5, 2026.

Original reporting
globenewswire.com
Published Oct 7, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PROF
Bullish
high confidence
Mentioned
$PROF
Relevance
6/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$PROFBullishMed
01

Why it matters

The preliminary revenue beat suggests accelerating adoption of its TULSA‑PRO and Sonalleve platforms, supporting a near‑term price rally.

02

Market read

First‑time disclosure of Q3 2026 revenue guidance, materially above consensus, likely to move the stock ahead of the full earnings release.

03

What to watch

Potential regulatory or reimbursement hurdles could temper revenue growth despite strong guidance.

Relevance 6/10Novelty 7/10Timing: ahead of full Q3 results on Nov 5

Background

Profound Medical is a commercial‑stage med‑tech company focused on MRI‑guided prostate and pain‑palliation therapies.

Company-level read

Ticker impact

$PROFBullishHigh confidence
Context

Profound Medical disclosed preliminary Q3 2026 revenue of $9.8‑$10.0 M, 85‑89% YoY growth and 45‑47% above consensus.

Expected impact

likely upward pressure as market prices in the strong top‑line beat

Evidence & confidence

Guidance is the first public disclosure and materially exceeds consensus, prompting short‑term buying interest.

Market effects

Sector

Positive signal for the interventional MRI device sector and related med‑tech peers.

Regional

May boost investor sentiment toward Canadian‑listed med‑tech firms.

Global

Limited to niche med‑tech space; no broad market effect.

Counterpoint

What could challenge this read

If the guidance proves overly optimistic, a subsequent miss could trigger a sharp correction.

Key entities

  • company
    Profound Medical Corp.

    NASDAQ‑listed med‑tech firm providing MRI‑guided therapeutic platforms.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 14
$PROFMedAI 8/10

Profound Medical says TULSA data show functional benefits, real-world validation and lower-field MRI feasibility

Profound Medical presented data at the 15th Interventional MRI Symposium showing TULSA's real-world performance and clinical benefits. Mayo Clinic studies reported high continence and erection preservation rates, sustained PSA decline, and shorter catheter days. The CAPTAIN trial showed TULSA's superiority in preserving erectile function and continence compared to robotic prostatectomy. Technical validation confirmed TULSA's feasibility on Siemens 0.55T Free.Max.

tradingview.com2 min
OCT 14
$PROFMedAI 8/10

Profound Medical Corp. (PROF): TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”

SEC EDGAR 8-K3 min
OCT 7
$PROFMed

Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg…

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (N

SEC EDGAR 8-K2 min
AUG 6
$PROFMed

Profound Medical Reports Second Quarter 2026 Financial Results

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Profound Medical Reports Second Quarter 2026 Financial Results – Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, c

SEC EDGAR 8-K6 min
OCT 28
$JMSBMed

John Marshall Bancorp, Inc. (JMSB): 3rd Quarter Net Income Increases 39.5% Versus Year Ago Quarter Funding, Asset Quality, and Capital Position Company for Anticipated Growth

John Marshall Bancorp, Inc. (JMSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 For Immediate Release October 28, 2026 ​ 3 rd Quarter Net Income Increases 39.5% Versus Year Ago Quarter Funding, Asset Quality, and Capital Position Company for Anticipated Growth ​ Reston, VA – John Marshall Bancorp, Inc. (Nasdaq: JMSB) (the “Company”), parent comp

SEC EDGAR 8-K2 min